Press "Enter" to skip to content

Healx collaborates on Angelman syndrome therapies

UK-based Healx will collaborate with the Foundation for Angelman Syndrome Therapeutics (FAST) to find and develop remedies for the dysfunction, which impacts roughly one in 15,000 folks worldwide. The partnership will use the corporate’s AI-powered know-how to discover potential remedies for Angelman syndrome, which assaults the nervous system.

The partnership is the newest collaboration originating from Healx’s Rare Treatment Accelerator (RTA) program. Launched in October 2019, the initiative is designed to convey collectively the corporate’s synthetic intelligence (AI) primarily based drug discovery know-how with affected person insights to foretell and validate new makes use of from already accepted medication, a course of reportedly proving faster, cheaper and safer than conventional discovery strategies.

Bruce Bloom, chief collaboration officer with Healx, instructed Outsourcing-Pharma that incorporating insights from sufferers is necessary within the pursuit of remedies for uncommon situations.

Patients and their families are at the very heart of everything we do, and we believe that by involving them from the outset, we can close the discovery research loop earlier, meaning we can find treatments faster​,” Bloom mentioned. “The Accelerator provides affected person teams the chance to collaborate with us to probably discover life-changing remedies for his or her uncommon illness – in a matter of years, versus many years​.”

Working together, we combine our AI technology, data, disease and drug discovery expertise to understand the disease, develop novel therapies and take them towards clinical trials in a typical timeframe of 24 months​,” Bloom added.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *